HA
VKTX icon

Harbor Advisors’s Viking Therapeutics VKTX Stock Holding History

Harbor Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Hold
10,500
– – 0.05% 138
2026
Q1 		$342K Hold
10,500
– – 0.05% 143
2025
Q4 		$369K Hold
10,500
– – 0.06% 139
2025
Q3 		$276K Hold
10,500
– – 0.04% 152
2025
Q2 		$278K Hold
10,500
– – 0.05% 153
2025
Q1 		$254K Hold
10,500
– – 0.04% 163
2024
Q4 		$423K Hold
10,500
– – 0.07% 127
2024
Q3 		$665K Hold
10,500
– – 0.11% 93
2024
Q2 		$557K Hold
10,500
– – 0.1% 99
2024
Q1 		$861K Buy
+10,500
New +$467K 0.16% 79

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Harbor Advisors's VKTX Position: Q2 2026 in Review

Harbor Advisors held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 10,500 shares worth $410K. The position accounts for 0.05% of the portfolio, ranked #138.

Harbor Advisors first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $861K in Q1 2024. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Harbor Advisors held 10,500 shares of Viking Therapeutics worth $410K as of Q2 2026.
  • Harbor Advisors left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.05% of Harbor Advisors's portfolio in Q2 2026, its #138 holding.
  • Harbor Advisors first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Harbor Advisors's Viking Therapeutics position peaked at $861K in Q1 2024.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Harbor Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.